Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
  • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
  • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses

Definitions

• the present invention relates to an oral pharmaceutical composition for the treatment of hepatitis B virus infection. More specifically, the present invention is directed to adhesive-free pharmaceutical compositions and pharmaceutical compositions comprising granules that are adhesive-free and comprise a guanine-based antiviral active pharmaceutical ingredient and manufacturing process of said pharmaceutical composition.
• Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection.
• Entecavir is a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV), which inhibits reverse transcription, DNA replication and transcription in the viral replication process.
• HBV hepatitis B virus
• Entecavir also helps to prevent the hepatitis B virus from multiplying and infecting new liver cells, is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection.
• entecavir 2-amino-l,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3 - (hydroxymethyl)-2-methylenecyclopentyl] -6H-purin-6-one, monohydrate. Its molecular formula is Ci 2 Hi 5 N 5 0 3 'H 2 0, which corresponds to a molecular weight of 295.3.
• Entecavir has the following structural formula:
• Entecavir is a slightly water soluble drug (2.4 mg/mL) and the pH of the saturated solution in water is 7.9 at 25° ⁇ 0.5° C. This leads to great difficulty in formulating immediate release dosage forms containing low dose content of entacavir. This, in turn, it makes it difficult to develop a robust formulation and a process for manufacturing same.
• Such low solubility can often result in poor dissolution behaviour, which can often result in low bioavailability, particularly given limited transit times through the gastrointestinal tract.
• BARACLUDE® is a film-coated tablet containing entecavir.
• the commercially available formulation of the BARACLUDE® film-coated tablets contain the following: entecavir as the active pharmaceutical ingredient (API) (0.5 mg and 1 mg) and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate.
• the tablet coating contains titanium dioxide, hypromellose, polyethylene glycol 400, polysorbate 80, and iron oxide red.
• Canadian Patent No. 2,053,339 (corresponds to U.S. Patent No. 5,206,244; and EP 0481754) discloses entecavir and its use in treating hepatitis B.
• This patent discloses that an effective antiviral dose for oral administration will be in the range of about 1.0 to 50 mg/kg of body weight and that the desired dose may be administered several times daily at appropriate intervals.
• Indian Patent Application No. IN2009MUM00913 discloses pharmaceutical compositions of entecavir for oral treatment of hepatitis B virus infection and/or co-infections and also relates to processes of preparation of such compositions, particularly direct compression is disclosed.
• WO 2011/128623 discloses a composition comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water- insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form.
• Canadian Patent Application No. 2,462,886 (corresponds to International Publication No. WO2003/030868) and Canadian Patent No. 2,311 ,734 disclose a flash-melt pharmaceutical dosage form comprising entecavir that rapidly disperses in the mouth, wherein a combination of superdisintegrants is utilized to enhance bioequivalence and stability. It discloses also that the flash-melt pharmaceutical dosage forms may be prepared by dry granulation of the excipients with the medicament and suitable conventional ingredients, such as flavouring and sweetening agents, without the use of any solvent, to form stable granules that can be readily compressed into dosage forms on conventional equipment without the need for special handling techniques.
• suitable conventional ingredients such as flavouring and sweetening agents
• Canadian Patent No. 2,401 ,569 (corresponds to International Publication No. WO 2001/064221 and EP 1267880) discloses a low dose entecavir formulation and uses thereof.
• the preferred pharmaceutical compositions contain from about 0.01 mg to about 10 mg of entecavir adhered to a pharmaceutically acceptable carrier substrate through the use of an adhesive substance, such as a polymeric material possessing a high degree of tackiness.
• Suitable adhesive materials include povidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, and xanthan gum and mixtures thereof with povidone being preferred.
• compositions are prepared by first carefully depositing the entecavir on the surface of the carrier substrate particles. This step is accomplished by forming a solution of the entecavir in a solvent along with an adhesive substance at temperatures ranging from about 25°C to about 80°C and applying the solution as a spray or a stream while the carrier substrate particles are in motion. The conditions are controlled to minimize particle agglomeration. Subsequently, the solvent is removed from the carrier surface leaving the entecavir particles adhered to the surface of the carrier substrate. This prevents the separation of the entecavir from the substrate and minimizes the loss of entecavir during subsequent processing.
• compositions taught are formulated for oral administration in the form of tablets or capsules, which further contain pharmaceutically acceptable excipients including bulking agents, lubricants, disintegrants, binding agents, etc. as commonly employed in such compositions.
• Such compositions cannot be prepared with good content uniformity by simply mixing the active substance and the excipients.
• the traditional methods of granulation are also not suitable for products containing active ingredients at such low doses.
• Canadian Patent No. 2,401 ,569 discloses the manufacture of low dose entecavir formulations utilizing an adhesive agent to prevent the separation of entecavir from the substrate.
• the solubility of entecavir in purified water is 2.4 mg/ml which is low and hence would require large amounts of solvent to be incorporated to the carrier substrate.
• Adding large amounts of solvent along with adhesive agent onto a carrier substrate by traditional methods of granulation like high shear granulation could lead to processing issues (over-granulation, loss of porosity of granules, less compaction, low dissolution, etc).
• Adding an adhesive agent to the solvent to make the API adhere to the carrier substrate and have good content uniformity would increase the complexity of manufacturing due to more binding of the solution to the carrier substrate coupled with the shear of mixing.
• Incorporating high amounts of solvent could be achieved by spray granulation process where the carrier particles are fluidized and the solvent is sprayed at a constant rate on to the carrier substrate.
• solubility of entecavir could be increased by adding pH adjusted water (by addition of acid or base in the purified water) which is not a common practice and could impart degradation to the product, since the drug is dissolved in the solvent.
• the present invention provides an adhesive-free pharmaceutical composition containing entecavir by wet granulation and pharmaceutical compositions comprising granules that are adhesive free and comprise entecavir.
• the present invention therefore, in turn mitigates or eliminates these limitations during formulation and manufacturing.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising: an adhesive-free granule which comprises at least one guanine-based antiviral active pharmaceutical ingredient and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and optionally a moisture barrier coating, wherein said composition is used for the treatment of hepatitis B virus infection.
• the present invention provides an adhesive-free pharmaceutical composition of entecavir that exhibits good stability when in the packaged product. It was established that, in certain cases, entecavir tablets coated with moisture barrier coatings (for example, PVA-based Opadry®, Opadry® AMB, Opadry® 200, etc.) provided some additional stability compared to normal hydroxypropylmethylcellulose (HPMC) based coatings.
• moisture barrier coatings for example, PVA-based Opadry®, Opadry® AMB, Opadry® 200, etc.
• a wet granulation process for manufacturing an adhesive-free pharmaceutical composition of entecavir is potentially simpler and less expensive than prior art processes.
• a pharmaceutical composition for oral administration comprising an adhesive-free granule which comprises at least one slightly soluble guanine-based antiviral active pharmaceutical ingredient and at least one intra- granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and optionally a moisture barrier coating, said adhesive-free pharmaceutical composition is used for the treatment of hepatitis B virus infection.
• the guanine-based antiviral active pharmaceutical ingredient of said pharmaceutical composition is entecavir or a pharmaceutically acceptable salt or solvate thereof.
• the amount of entecavir in said composition ranges from about 0.1 mg to about 5.0 mg. In preferred embodiments of the present invention, the amount entecavir present is about 0.1 mg, about 0.5 mg and about 1.0 mg.
• compositions comprising entecavir or a pharmaceutically acceptable salt or solvate thereof, along with at least one pharmaceutically acceptable excipient selected from the group consisting of: fillers, diluents, lubricants, disintegrants, coating polymers and combinations thereof.
• the filler is selected from the group consisting of: cellulose, dibasic calcium phosphate, calcium carbonate, microcrystalline cellulose, sucrose, lactose, glucose, mannitol, sorbitol, maltol, pregelatinized starch, corn starch, potato starch and combinations thereof.
• the filler is lactose monohydrate and is present in an amount ranging from about 30% w/w to about 70% w/w of the total composition.
• the filler is microcrystalline cellulose and is present in an amount ranging from about 30% w/w to about 70% w/w of the total composition.
• the disintegrant is selected from the group consisting of: crospovidone, sodium starch glycolate, sodium pregelatinized starch, modified corn starch and combinations thereof. More preferably, the disintegrant is crospovidone and is present in an amount ranging from about 2.0% w/w to about 10% w/w of the total composition.
• the lubricant is selected from the group consisting of: magnesium stearate, calcium stearate, zinc stearate, sodium stearate, stearic acid, aluminum stearate, glyceryl behenate, hydrogenated vegetable oil and combinations thereof.
• the lubricant is magnesium stearate and is present in an amount ranging from about 0.1 % w/w to about 2% w/w of the total composition.
• the moisture barrier coating is selected from the group consisting of: PVA-based Opadry ®, Opadry ®AMB, Opadry ⁇ 200, and mixtures thereof.
• the present invention is directed to an adhesive-free pharmaceutical composition for oral administration comprising: entecavir, lactose, microcrystalline cellulose, crospovidone, magnesium stearate, and optionally moisture barrier coating, wherein said composition is in the form of a tablet or a capsule.
• Another aspect of the present invention provides for a method of manufacturing an adhesive-free pharmaceutical composition comprising following steps:
• an adhesive-free pharmaceutical composition for oral administration comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra- granular pharmaceutical excipient, and optionally a moisture barrier coating, wherein said process comprising following steps:
• step (3) (4) adding the granulation solution of step (2) to the mixing blend of step (3);
• step (6) screening the dried granules of step (6) to obtain uniform lump free granules
• step (8) adding the screened granules of step (7) to a bin blender;
• step (9) adding microcrystalline cellulose and crospovidone to the blend of step (8) and mixing;
• step (10) adding granules of step (10) to the blend of step (9) and mixing;
• step (12) optionally coating the content of step (12) with coating dispersion.
• the present invention also relates to the use of an adhesive-free pharmaceutical composition for the treatment of patients having hepatitis B virus infection, such compositions comprising entecavir in an amount ranging from about 0.1 mg to about 5.0 mg.
• active ingredient and “active agent” (as well as other terms a person skilled in the art would be well aware of) refers to an active pharmaceutical ingredient (API) which is the active chemical used in the manufacturing of drugs.
• the active agent can be a therapeutic, a prophylactic, or a diagnostic agent.
• terapéuticaally effective amount intends to describe an amount of the active agent which stops or reduces the progress of the condition intended to be treated or which otherwise completely or partly cures or acts palliative on the condition.
• Adhesive-free granules is used to describe granules containing the guanine-based antiviral active pharmaceutical ingredient with at least one intra-granular pharmaceutically acceptable excipient that are free of adhesive substances or materials.
• Adhesive substances include polymeric material possessing a high degree of tackiness. Suitable adhesive materials include povidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, and xanthan gum and mixtures thereof.
• the guanine-based antiviral active pharmaceutical ingredient is selected from the group consisting of antiviral agents.
• the antiviral agent is lamivudine, pegylated interferon, adefovir, entecavir, telbivudine, tenofovir and combinations thereof. More preferably, the antiviral agent is entecavir.
• the pharmaceutical composition according to the present invention contains at least one pharmaceutically acceptable excipient added to the composition for various purposes.
• At least one pharmaceutically acceptable excipient may be present in the formulation of the present invention, but not limited to: diluents, fillers, binders, lubricants, disintegrants, glidants, and acidifying agents. As understood by a person skilled in the art, these excipients are standard and well known in the pharmaceutical art.
• the filler according to the present invention is selected from the group consisting of: cellulose, microcrystalline cellulose, dibasic calcium phosphate, calcium carbonate, sucrose, lactose, glucose, mannitol, sorbitol, maltol, pregelatinized starch, corn starch, potato starch and combinations thereof.
• the filler is selected from the group consisting of: lactose monohydrate and microcrystalline cellulose, alone or in combination.
• the disintegrant according to the present invention is selected from the group consisting of: crospovidone, sodium starch glycolate, sodium pregelatinized starch, modified corn starch and combinations thereof.
• the disintegrant is crospovidone.
• the lubricant according to the present invention is selected from the group consisting of: magnesium stearate, calcium stearate, zinc stearate, sodium stearate, stearic acid, aluminum stearate, glyceryl behenate, hydrogenated vegetable oil and combinations thereof.
• the lubricant is magnesium stearate.
• the moisture barrier coating is selected from the group consisting of: PVA-based Opadry ®, Opadry ®AMB, Opadry ⁇ 200, and mixtures thereof.
• Opadry® is a registered trade mark of Colorcon Inc.
• the present invention discloses a stable, adhesive-free, pharmaceutical composition of entecavir, having a USP acceptance value for content uniformity of 85% to 1 15 % by weight and a relative standard deviation (RSD) of less than 6 %.
• Stability data in ALU/ALU cold forming blister at 40°C and 75% RH for 1 month shows an unknown degradation product at RRT 1.98, which does not increase for the tablets coated with moisture barrier coatings as compared to tablets coated with normal non barrier coating system.
• These adhesive-free pharmaceutical compositions exhibit good content uniformity and stability.
• entecavir The required quantity of entecavir (2.65 g) was dissolved in a hydro alcoholic solution containing 50:50 v/v (540. Og) of dehydrated alcohol and purified water under stirring at room temperature. Stirring was continued until a clear solution was obtained. This solution was used as granulating solution.
• Step 2 Granulation Lactose monohydrate, microcrystalline cellulose and crospovidone XL were added to high shear granulator in required quantities (see Table 1 ) and mixed for 5 minutes.
• the granulating solution of step 1 was added to the high shear bowl under mixing. Once the solution was added completely the container was rinsed with 50:50 v/v dehydrated alcohol and purified water. This solution was also added to the high shear bowl under mixing.
• step (2) The wet granules of step (2) were dried in a fluid bed until a loss on drying (LOD) value of 2-3% was obtained. Then, dried granules of previous step were screened through a 1 100 ⁇ screen to obtain uniform lump free granules.
• LOD loss on drying
• Step 4 Extra granular mixing
• step (3) The screened granules of step (3) were added to a bin blender.
• the required quantity of microcrystalline cellulose and crospovidone XL was adjusted based on the yield of granules of previous step.
• These ingredients were screened manually through a 425 ⁇ screen and were added to blender and blended for 10 minutes.
• the required quantity of magnesium stearate (see Table 1 ) was adjusted based on the yield of granules and further screened manually through a 425 ⁇ screen and added to blender of step (4) and was blended for 2 minutes.
• the obtained blend was compressed on a compression machine at an average weight of 200mg to obtain 0.5mg per tablet of entecavir (see Table 1 ).
• Example 1 The formulation and manufacturing steps of Example 1 is set out in Table 1.
• Table 1 Formulation and Manufacturing steps.
• Tablets manufactured as per Example 1 further were coated with a moisture barrier coating system.
• Tablets manufactured as per Example 1 were further coated with two different coating systems one with non-moisture barrier coating system and other with a moisture barrier coating system to evaluate stability of packaged finished product.
• a comparative stability data is summarized in Table 3.
• Tablets coated with non-moisture barrier coating system were designated as Formulation A.
• Tablets coated with moisture barrier coating system were designated as Formulation B.
• Tablets coated with moisture barrier coating system were designated as Formulation C.
• Tablets coated with moisture barrier coating system were designated as Formulation D.
• Tablets manufactured as per Example 1 were further coated with two different coating systems one with non-moisture barrier coating system and other with moisture barrier coating system to evaluate stability of packaged finished product.
• a comparative stability data is summarized in Table 4.
• RRT relative retention time
• Formulation A tablets coated with non-moisture barrier coating system (HPMC based Opadry®); Formulation B -tablets coated with moisture barrier coating system (PVA based Opadry®):
• Formulation C- tablets coated with moisture barrier coating system (Opadry® AM B);
• Formulation D- tablets coated with moisture barrier coating system (Opadry®200).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Virology (AREA)
• Oncology (AREA)
• Biotechnology (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=49672225

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (6)

Citations (4)

Family Cites Families (10)

• 2012
  • 2012-05-31 CA CA 2779052 patent/CA2779052A1/en not_active Abandoned
• 2013
  • 2013-05-28 HK HK15109146.7A patent/HK1208620A1/xx unknown
  • 2013-05-28 EP EP13797878.9A patent/EP2854773B1/en active Active
  • 2013-05-28 JP JP2015514297A patent/JP6320371B2/ja active Active
  • 2013-05-28 CN CN201380030696.6A patent/CN104363896A/zh active Pending
  • 2013-05-28 CA CA2874779A patent/CA2874779C/en active Active
  • 2013-05-28 US US14/404,176 patent/US20150110869A1/en not_active Abandoned
  • 2013-05-28 WO PCT/CA2013/000517 patent/WO2013177672A1/en not_active Ceased
  • 2013-05-28 IN IN2487MUN2014 patent/IN2014MN02487A/en unknown
  • 2013-05-28 KR KR20147034899A patent/KR20150015500A/ko not_active Ceased
• 2018
  • 2018-04-03 US US15/944,452 patent/US20190076366A1/en not_active Abandoned

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events